Zobrazeno 1 - 10
of 552
pro vyhledávání: '"Peter Hillmen"'
Autor:
Matthew Holmes, Gina B. Scott, Samuel Heaton, Tyler Barr, Basem Askar, Louise M.E. Müller, Victoria A. Jennings, Christy Ralph, Cathy Burton, Alan Melcher, Peter Hillmen, Christopher Parrish, Fiona Errington-Mais
Publikováno v:
Molecular Therapy: Oncolytics, Vol 29, Iss , Pp 17-29 (2023)
Primary drug resistance and minimal residual disease are major challenges in the treatment of B cell neoplasms. Therefore, this study aimed to identify a novel treatment capable of eradicating malignant B cells and drug-resistant disease. Oncolytic v
Externí odkaz:
https://doaj.org/article/5203c050e9894f55a9405ad6fce9ab42
Autor:
Richard Kelly, Hisakazu Nishimori, Regina Horneff, Peter Hillmen, Jessica Savage, Mohammed Al-Adhami, Stacie Lallier, Gloria Gerber
Publikováno v:
HemaSphere, Vol 7, p e66610c4 (2023)
Externí odkaz:
https://doaj.org/article/45057cbce2b34ab3b9c8abb2425525ca
Autor:
Peter Hillmen, Jing Xie, Alan S. M. Yong, Catherine Waweru, Thuy Anh Sorof, Ravi K. Goyal, Keith L. Davis
Publikováno v:
eJHaem, Vol 2, Iss 2, Pp 219-227 (2021)
Abstract Chronic lymphocytic leukaemia (CLL) is the most common leukaemia in adults in the UK. Ibrutinib, an oral Bruton tyrosine kinase inhibitor (BTKi) for CLL approved by the UK's National Institute for Health and Care Excellence in January 2017,
Externí odkaz:
https://doaj.org/article/64a0d007117945a597b923277fa9e33d
Autor:
Dena R. Howard, Anna Hockaday, Julia M. Brown, Walter M. Gregory, Susan Todd, Tahla Munir, Jamie B. Oughton, Claire Dimbleby, Peter Hillmen
Publikováno v:
Trials, Vol 22, Iss 1, Pp 1-13 (2021)
Abstract Background The FLAIR trial in chronic lymphocytic leukaemia has a randomised, controlled, open-label, confirmatory, platform design. FLAIR was successfully amended to include an emerging promising experimental therapy to expedite its assessm
Externí odkaz:
https://doaj.org/article/f5a4a538c4cd4e3c8cd38fb1ff778296
Autor:
Wei-Yu Lin, Sarah E. Fordham, Nicola Sunter, Claire Elstob, Thahira Rahman, Elaine Willmore, Colin Shepherd, Gordon Strathdee, Tryfonia Mainou-Fowler, Rachel Piddock, Hannah Mearns, Timothy Barrow, Richard S. Houlston, Helen Marr, Jonathan Wallis, Geoffrey Summerfield, Scott Marshall, Andrew Pettitt, Christopher Pepper, Christopher Fegan, Francesco Forconi, Martin J. S. Dyer, Sandrine Jayne, April Sellors, Anna Schuh, Pauline Robbe, David Oscier, James Bailey, Syed Rais, Alison Bentley, Lynn Cawkwell, Paul Evans, Peter Hillmen, Guy Pratt, David J. Allsup, James M. Allan
Publikováno v:
Nature Communications, Vol 12, Iss 1, Pp 1-8 (2021)
The clinical course of chronic lymphocytic leukaemia (CLL) is variable and difficult to predict. Here, the authors conduct a genome wide association study meta-analysis for time to first treatment in CLL patients and report two loci associating with
Externí odkaz:
https://doaj.org/article/326c1d18f1cc498d8b36824ed27e2e04
Publikováno v:
Molecular Oncology, Vol 14, Iss 6, Pp 1268-1281 (2020)
Cross‐linking of the B‐cell receptor (BCR) induces transcriptional activation of immediate early genes (IEGs) including EGR1 and DUSP2 in chronic lymphocytic leukaemia (CLL). Here, we have shown that this transcriptional activation correlated wit
Externí odkaz:
https://doaj.org/article/e1a16b42b1b04727afc2b91d8753eff2
Autor:
Jennifer R. Brown, John C. Byrd, Paolo Ghia, Jeff P. Sharman, Peter Hillmen, Deborah M. Stephens, Clare Sun, Wojciech Jurczak, John M. Pagel, Alessandra Ferrajoli, Priti Patel, Lin Tao, Nataliya Kuptsova-Clarkson, Javid Moslehi, Richard R. Furman
Publikováno v:
Haematologica, Vol 107, Iss 6 (2021)
Cardiovascular (CV) toxicities of the Bruton tyrosine kinase (BTK) inhibitor ibrutinib may limit use of this effective therapy in patients with chronic lymphocytic leukemia (CLL). Acalabrutinib is a second-generation BTK inhibitor with greater BTK se
Externí odkaz:
https://doaj.org/article/539d278310f84aa3955bb4b7eb5f3b1d
Autor:
Niamh Appleby, Toby A. Eyre, Maite Cabes, Aimee Jackson, Rebecca Boucher, Francesca Yates, Sonia Fox, Andrew Rawstron, Peter Hillmen, Anna Schuh
Publikováno v:
BMC Cancer, Vol 19, Iss 1, Pp 1-12 (2019)
Abstract Background Transformation of chronic lymphocytic leukaemia (CLL) to diffuse large B-cell lymphoma (DLCBL) type Richter’s syndrome (RS) carries a dismal prognosis. Standard-of-care chemoimmunotherapy for de novo RS is inadequate with median
Externí odkaz:
https://doaj.org/article/15ead9c66a094069a1a882e50217e02a
Autor:
Constantine S. Tam, Tadeusz Robak, Paolo Ghia, Brad S. Kahl, Patricia Walker, Wojciech Janowski, David Simpson, Mazyar Shadman, Peter S. Ganly, Luca Laurenti, Stephen Opat, Monica Tani, Hanna Ciepluch, Emma Verner, Martin Šimkovič, Anders Österborg, Marek Trněný, Alessandra Tedeschi, Jason C. Paik, Sowmya B. Kuwahara, Shibao Feng, Vanitha Ramakrishnan, Aileen Cohen, Jane Huang, Peter Hillmen, Jennifer R. Brown
Publikováno v:
Haematologica, Vol 106, Iss 9 (2020)
Patients with chronic lymphocytic leukemia or small lymphocytic lymphoma whose tumors carry deletion of chromosome 17p13.1 [del(17p)] have an unfavorable prognosis and respond poorly to standard chemoimmunotherapy. Zanubrutinib is a selective next-ge
Externí odkaz:
https://doaj.org/article/8f75524183cd439aaa1541ae95718eb4
Autor:
Davide Rossi, Mazyar Shadman, Adalgisa Condoluci, Jennifer R. Brown, John C. Byrd, Gianluca Gaidano, Michael Hallek, Peter Hillmen, Anthony Mato, Emili Montserrat, Paolo Ghia
Publikováno v:
HemaSphere, Vol 4, Iss 4, p e432 (2020)
Abstract. Infections are a major cause of morbidity and mortality in patients with chronic lymphocytic leukemia (CLL). These can be exacerbated by anti-leukemic treatments. In addition, the typical patients with CLL already have fragilities and backg
Externí odkaz:
https://doaj.org/article/625f1593a816404b8d6b26698be15c38